Table 8.
HDAC-Is in clinical trials for CTCL
| HDAC-I in clinical trials for CTCL | Dosage | Favorability | Limitations |
|---|---|---|---|
| SAHA | 400 mg PO daily | No IV access, no risk of sepsis, high tolerability | Fatigue, thrombocytopenia, pulmonary embolus, nausea |
| Depsipeptide | 14 mg/m2 IV day 1, 8, 15 of each month | Rapid decrease of Sezary cells and erythroderma | IV access with higher risk of sepsis, cardiac effects such as QT prolongation and arrhythmia |
| PXD-101 | 1000 mg/m2 every 3 weeks | No hematological toxicity was identified | IV access with higher risk of sepsis, atrial fibrillation, diarrhea, fatigue |
| LBH 589 | 20 mg or 30 mg PO MWF in a 28 days cycle | No IV access, no risk of sepsis | Diarrhea, atrial fibrillation, fatigue, neutropenia, thrombocytopenia, anemia |